Researchers conducted an eight-center study on how Cellvizio aided in Barrett’s Esophagus detection, recruiting 172 patients. Researchers compared confocal laser endomicroscopy with conventional histology to the Seattle Protocol.
Here’s what they found:
1. Novice probe-based confocal laser endomicroscopy doubled the identification rate of Barrett’s Esophagus (99) over the Seattle Protocol (46).
2. Cellvizio and biopsies confirmed Barrett’s Esophagus was detected by Cellvizio in 56 of 61 patients with negative biopsies.
3. Researchers found no statistically significant difference between novice pCLE users and expert review.
4. Mauna Kea CEO and Co-Founder Sacha Loiseau, PhD, said, “The study demonstrates the broad applicability of pCLE for routine esophageal surveillance. This publication establishes further validation to Cellvizio’s superior sensitivity in the detection of Barrett’s Esophagus compared to standard protocol and provides a major advancement towards more accurate identification of individuals at risk for esophageal adenocarcinoma.”
More articles on gastroenterology:
New drug prevents pancreatic cancer in mice — 3 insights
The Luminary Awards in GI Cancer recognize 5 honorees — 7 insights
A better capsule endoscopy? — U of Utah researchers developing autonomous robot: 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.